Google Announces Partnership with Gentle Monster as a First Partner for AI Smart Eyewear with Android XR
SINGAPORE, May 21, 2025 /PRNewswire/ -- Google announced at I/O 2025 its partnership with Gentle Monster as a first partner for an AI smart eyewear collaboration with Android XR.
Gentle Monster is a global eyewear brand from South Korea, leading the trends in global eyewear through its innovative brand narrative with experimental yet sophisticated aesthetics.
Shahram Izadi, General Manager and Vice President, Google XR, emphasized that creativity and sophistication are essential design features for technology to integrate into everyday life. Gentle Monster as a first partner in the development of AI smart eyewear with Android XR was also highlighted as a pivotal step in the evolution of AI smart eyewear into essential, lifestyle fashion items.
Envisioning easy-to-wear products with both comfort and aesthetics as top priorities, the new partnership with Gentle Monster is set to seamlessly integrate extended reality into everyday life.
The announcement at Google I/O 2025 has sparked considerable anticipation for the eyewear that will showcase cutting-edge smart technology alongside the refined aesthetics of Gentle Monster.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
Korea Herald
a day ago
- Korea Herald
Tianfu Rapoil Shines at Hong Kong Hometown Market Carnival
HONG KONG, June 1, 2025 /PRNewswire/ -- This is a report from Xinhuanet: Co-organized by 30 provincial-level hometown associations in Hong Kong, the "Third Hometown Market Carnival" was kicked off on June 1 in Victoria Park, marking the beginning of the five-day event. The Sichuan Provincial Grain and Material Reserve Bureau showcased its premium products under the 'Tianfu Rapoil' brand at the event, becoming the star attraction in this year. At the event, Tianfu Rapoil brought nearly 2,000 products, ranging from 'Traditional Small-Pressed Rich-Aromatic Rapeseed Oil' made using non-heritage pressing techniques, to low-erucic acid rapeseed oil, and small-packaged rapeseed oil specifically designed for younger consumers. On-site, residents and tourists participated in 'Come to Play and Win Oil in Victoria Park'. They not only won Tianfu Rapoil products but also received its limited-edition cultural and creative merchandise. Items such as umbrellas, folding fans, and canvas bags featuring panda patterns became the most sought-after items at the event. This year's Hong Kong Hometown Market Carnival features a special Chinese Food Street, with 30 food stalls offering cuisines from all over China. When Tianfu Rapoil meets regional specialities such as Xinjiang lamb skewers, Shaanxi Roujiamo, and Hunan Changde rice noodles, magical sparks occur. At Xinjiang association stall, chefs blended Tianfu rapeseed oil with cumin and chili powder to create a secret sauce brushed onto sizzling lamb skewers, drawing a snaking line of eager customers. At Shaanxi association stall, chefs tried Tianfu rapeseed oil to bake Roujiamo, praised by diners as a 'soulful carb bomb'. At Hunan association stall, chefs used Tianfu rapeseed oil to prepare the special topping for Changde rice noodles, delighting noodle lovers with its fragrant and refreshing taste. During the event, procurement managers from local Hong Kong catering groups and buyers from high-end supermarkets were drawn by the aroma. "The fragrance of Tianfu Rapoil is unique. After testing it in cooking, we noticed a significant improvement in the dishes' flavor," said a procurement representative from a well-known chain restaurant, who expressed immediate interest in establishing a stable supply channel after learning about the oil's production process and quality standards. The flood of partnership inquiries reflects the robust strength of Sichuan's rapeseed industry. As the province with the largest rapeseed cultivation area and the highest rapeseed oil consumption in China, Sichuan has in recent years taken the Tianfu Rapoil initiative as a starting point to drive the upgrading of the entire industrial chain, and enabled Tianfu Rapoil to stand out in the domestic edible oil sector, winning the 'China Grain and Oil Influential Public Brand' award for five consecutive years, with a brand value exceeding 10 billion yuan.
Korea Herald
a day ago
- Korea Herald
Fall of Mongolian coalition government could lead to severe economic downturn
ULAANBAATAR, Mongolia, June 1, 2025 /PRNewswire/ -- As Mongolia's parliament prepares to vote on Monday on whether the country's coalition government should remain in office, new economic analysis warns that the demise of the government could see the size of Mongolia's economy contract by over 20% within six months, and FDI fall by almost 40% year-on-year. Prime Minister Oyun-Erdene called on Wednesday for members of the Great State Khural to decide on whether the coalition government, which has been in place since last June's parliamentary elections, should remain as a way of ending recent political instability. The Prime Minister is due to address the Khural on Monday ahead of a 'confidence vote' – likely to be deemed one of the most important moments in Mongolia's political history since becoming a democracy in the early 1990s. As the vote approaches, new economic data – which can be viewed in full here – produced by Mongolia's Economic Development Board warns of the scale of the economic hit Mongolia could face, namely: These forecasts are in line with the experiences of other countries where political instability has had a negative impact on the economy, including following the fall of a coalition government: Commenting, Dr Batnasan B., Professor at the Business School of the National University of Mongolia and Member of the Economic Development Board, said: " The latest data clearly highlights the potential economic consequences of a collapse in Mongolia's coalition government: a sharp economic downturn, runaway inflation, and a rise in unemployment. "It is entirely appropriate that elected representatives decide who governs the country. But it is equally important that such decisions are made with full access to the facts and a clear understanding of the potential risks. "The Economic Development Board's analysis—combined with lessons from other countries that have faced similar circumstances—presents a compelling warning: all the hard-won economic progress Mongolia has achieved in recent years could be jeopardized if Monday's vote results in increased political instability." This new analysis, as well as precedent from around the world, clearly shows the magnitude of the decision to be taken by lawmakers on Monday, and the jeopardy to the significant economic progress Mongolia has made since the COVID-19 pandemic, including adding $9 billion USD to its economy and increasing GDP per capita by an additional $2,400.
